Oral Cavity Carcinoma — Trials

Oral Cavity Carcinoma — Trials · CancerIndex

Clinical trials

Registered studies

310 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 94
Recruiting: 43
Ph III recruiting: 9
Growth YoY: +13.6%
Industry share: 6%
Top sponsor: National Cancer Institute (NCI)
Termination share: 33.6%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (38)

clinicaltrialsPublishedShowing 51–55 of 55 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT05098119	Neoadjuvant Sintilimab Combined With Reduction of Cycles of Chemotherapy in Resectable Oral Cavity or Oropharyngeal Squamous Cell Carcinoma (OOC-002)	recruiting	Phase 2	43	Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER	1	Mar 26, 2024	clinicaltrials
NCT05069857	Neoadjuvant Personalized Anti-PD-1 and Anti-VEGFR Therapy in OSCC Patients	recruiting	Phase 2	46	Shanghai Jiao Tong University School of MedicineOTHER	1	Nov 22, 2023